ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
November 07 2017 - 3:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the following presentations by Company
management at upcoming investor conferences will be webcast:
- Jefferies 2017 London Healthcare
ConferenceNovember 15, 2017 at 10:40am GMT
- Evercore ISI Biopharma Catalyst/Deep
Dive ConferenceNovember 30, 2017 at 3:30pm ET
A webcast of each presentation will be accessible through the
Investors section of the Company's website, www.immunogen.com.
Following the live webcast, a replay will be available at the same
location for approximately two weeks.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted cancer therapeutics using its proprietary ADC
technology. The Company’s lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in a Phase 1b/2
trial in combination regimens for earlier-stage disease. ImmunoGen
has three additional clinical-stage product candidates, two of
which are being developed in collaboration with Jazz
Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's
marketed product, Kadcyla®, and in programs in development by
Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi
and Takeda. More information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to preclinical
and clinical studies, their timings and results. A review of these
risks can be found in ImmunoGen's Transition Report on Form 10-K
for the fiscal year ended December 31, 2016 and other
reports filed with the Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171107006576/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI Consulting
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024